Glycogen synthase kinase-3 and leukemia: restoring the balance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

1. Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.Cells · 2020
   Review
2. Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPCell death & disease · 2018
   Article
3. Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth.Oncogene · 2015
   Article
4. Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1.Oncogene · 2014
   Article
5. Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives.Rheumatology international · 2012
   Review

Corrections and comments

• Comment on
  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.2010

Authors and funding

2 authors at 1 institution in 1 country.

Funding

Abstract